IL-10 mRNA-LNP
Pre-clinical- Indications
- Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease
Company intelligence / Profile preview
Propria provides advanced in vitro cardiac contractility testing using proprietary engineered human heart tissues derived from iPSC-cardiomyocytes. Their patented platform enables comprehensive, realistic profiling of human cardiac muscle function to support drug discovery, disease modeling, and cardiotoxicity assessment. The company partners with academic groups and major pharmaceutical/biotech companies to deliver high-quality data that better predicts human pharmacology outcomes.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Propria.